Daré Bioscience, Inc. Prices Underwritten Public Offering of Common Stock
April 09 2019 - 8:45AM
Daré Bioscience, Inc. (NASDAQ:DARE), today announced the pricing of
an underwritten public offering of 4,575,000 shares of its common
stock at a price of $1.10 per share. The company has also granted
to the underwriters a 30-day option to acquire an additional
686,250 shares to cover overallotments in connection with the
offering. After the underwriting discount and estimated offering
expenses payable by the company, the company expects to receive net
proceeds of approximately $4.4 million, assuming no exercise of the
overallotment option, and approximately $5.1 million assuming the
overallotment option is exercised in full. The offering is expected
to close on April 11, 2019, subject to customary closing
conditions.
Roth Capital Partners is acting as the sole
book-runner for the offering. Aegis Capital Corp. is acting as
co-manager for the offering.
The company intends to use the net proceeds from
the offering for working capital and general corporate purposes,
including to advance its product candidate portfolio and general
and administrative expenses.
The shares described above are being offered
pursuant to a registration statement previously filed with and
subsequently declared effective by the Securities and Exchange
Commission.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy any of the
securities described herein, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction. Copies of the preliminary prospectus supplement and
accompanying base prospectus relating to this offering may be
obtained from Roth Capital Partners, 888 San Clemente Drive, Suite
400, Newport Beach, CA 92660, (800) 678-9147 or by accessing the
SEC’s website, www.sec.gov.
About Daré Bioscience
Daré Bioscience is a clinical-stage
biopharmaceutical company committed to the advancement of
innovative products for women’s health. The company’s mission is to
identify, develop and bring to market a diverse portfolio of
differentiated therapies that expand treatment options, improve
outcomes and facilitate convenience for women, primarily in the
areas of contraception, vaginal health, sexual health, and
fertility.
Daré’s product portfolio includes potential
first-in-class candidates in clinical development: Ovaprene®, a
non-hormonal, monthly contraceptive intravaginal ring; Sildenafil
Cream, 3.6%, a novel cream formulation of sildenafil to treat
female sexual arousal disorder utilizing the active ingredient in
Viagra®; DARE-BV1, a unique hydrogel formulation of clindamycin
phosphate 2% to treat bacterial vaginosis via a single application;
and DARE-HRT1, a combination bio-identical estradiol and
progesterone intravaginal ring for hormone replacement therapy
following menopause. To learn more about Daré’s full portfolio of
women’s health product candidates, and mission to deliver
differentiated therapies for women, please visit
www.darebioscience.com.
Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of The Private Securities Litigation
Reform Act of 1995 regarding matters that are not historical facts,
including statements relating to Daré's expectations regarding the
completion of the public offering, the net proceeds therefrom and
the company’s proposed use of proceeds. Forward-looking statements
are subject to known and unknown risks and uncertainties, many of
which may be beyond our control. We caution you that the
forward-looking information presented in this press release is not
a guarantee of future events, and that actual events may differ
materially from those made in or suggested by the forward-looking
information contained in this press release. In addition, any
forward-looking statements included in this press release represent
our views only as of the date of this release and should not be
relied upon as representing our views as of any subsequent date.
Daré specifically disclaims any obligation to update any
forward-looking statements included in this press release.
Contacts:
Investors on behalf of Daré Bioscience, Inc.: Alex
GrayBurns McClellanagray@burnsmc.com212-213-0006
OR
Media on behalf of Daré Bioscience, Inc.Amanda GuisbondCanale
Communicationsamanda@canalecomm.com781-405-8775
Source: Daré Bioscience
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Apr 2023 to Apr 2024